ArticlePloS one2017
Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines for pre-analytical conditions for assessing the methylation of circulating cell-free DNA.Clinical epigenetics · 2021Pooled it
- Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019Trial
- Extrapulmonary and OtherJournal of fungi (Basel, Switzerland) · 2026Article
- Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.Cancer discovery · 2024Article
- Synthesis of positive plasmas with known chromosomal abnormalities for validation of non-invasive prenatal screening.Frontiers in genetics · 2023Article
- A novel method for extracting circulating cell-free DNA from whole blood samples and its utility in the non-invasive prenatal test.Prenatal diagnosis · 2022Article
- Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors.International journal of molecular sciences · 2021Review
- Total and endothelial cell-derived cell-free DNA in blood plasma does not change during menstruation.PloS one · 2021Article
- UltraPrep is a scalable, cost-effective, bead-based method for purifying cell-free DNA.PloS one · 2020Article
- Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements.The Journal of molecular diagnostics : JMD · 2019Article
- A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.Journal of the National Cancer Institute · 2019Article
- Liquid biopsy in pancreatic cancer: the beginning of a new era.Oncotarget · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The breadth of diagnostic procedures that utilize cell free DNA (cfDNA) from human plasma has increased dramatically in recent years. Here, we confirm that tumor-derived cfDNA fragments are similar in size distribution to cfDNA derived from normal tissues. Therefore, collection procedures optimized with healthy donor specimens are likely to be applicable to the diagnosis and monitoring of many different cancer types. We verify that the distribution and DNA sequences of fragmentation sites in cfDNA from both normal-germline and tumor-derived cfDNA are non-random. A broad survey of cfDNA from healthy donors suggests that average individuals possess ~6 ng of cfDNA per mL of plasma. Importantly, the cfDNA present in plasma samples that were initially collected as whole blood in K2-EDTA tubes and subsequently processed by centrifugation is stable for several days at ambient temperatures. This observation has the potential to significantly reduce the cost and logistical complexity of shipping clinical samples from the site of collection to centers proficient in diagnostic analysis. Finally, plasma samples collected with high-volume plasma collection devices possess abundant quantities of cfDNA. Since the quantity of analyzed cfDNA is directly proportional to sensitivity of diagnostic assays, this method of plasma collection, where available, could enable highly sensitive post-treatment disease monitoring and early detection of cancer in at-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.